Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.61 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.40 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3875424 | 0.79 | SIGMAR1 (0.41) | TAAR1TSHRL3MBTL1ALDH1A1LMNA | |
| SCHEMBL4751966 | 0.75 | TSHR (0.43) | TSHRL3MBTL1LMNA | |
| SCHEMBL5420858 | 0.70 | TSHR (0.39) | TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL11738260 | 0.69 | NPC1 (0.41) | TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL11674029 | 0.68 | HTT (0.42) | TSHRALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL11741941 | 0.67 | KDM4E (0.41) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL11768890 | 0.66 | TSHR (0.38) | TSHRL3MBTL1ALDH1A1LMNA | |
| SCHEMBL6530065 | 0.66 | CYP1A2 (0.39) | TSHRL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1807709 | 0.66 | OPRL1 (0.53) | TAAR1OPRL1RORC | |
| SCHEMBL31387399 | 0.63 | OPRL1 (0.47) | TAAR1OPRL1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1409476-B1 | PHARMACEUTICAL COMPOUNDS WITH SEROTONIN RECEPTOR ACTIVITY | LILLY CO ELI (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040180883-A1 | Pharmaceutical compounds with serotonin receptor activity | GILMORE JEREMY (GB) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180883-A1 | Pharmaceutical compounds with serotonin receptor activity | HTR1A, HTR5A, HTR1E | TAAR1 150/4885OPRL1 30/4885MAP3K14 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.